A 3D brain unit model to further improve prediction of local drug distribution within the brain
read more
Citations
Stent elution rate determines drug deposition and receptor-mediated effects
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
EFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 1. Development of Physiologically‐Based Kinetic (PBK) Model Coupled With Pulmonary and Dermal Exposure
Measurement and Modeling of Transport Across the Blood-Brain Barrier.
References
Influence of passive permeability on apparent P-glycoprotein kinetics.
Diffusion of molecules in brain extracellular space: theory and experiment.
Stent elution rate determines drug deposition and receptor-mediated effects
Distributed model for drug delivery to CSF and brain tissue
Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model.
Related Papers (5)
Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.
Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier.
Frequently Asked Questions (2)
Q2. What are the future works mentioned in the paper "A 3d brain unit model to further improve prediction of local drug distribution within the brain" ?
However, for drugs that do bind plasma proteins, the assumption is likely violated with an impact to be investigated in future work. In similar fashion, assumptions 2 ( ii ), 2 ( iv ) and 2 ( vii ) are not violated for drugs that do not cross cells, but it is likely that for drugs that do, they are violated with an impact to be investigated in future work. With the establishment of the current 3D brain unit model, the authors are now ready to incorporate intra-extracellular exchange and drug binding to intracellular binding sites in future modelling work. It is anticipated that in certain cases, like those of high drug-target binding or active transport, these differences may also exist on a larger time-scale, but this requires further investigation.